Biofrontera Inc Total Liabilities
Biofrontera Inc total liabilities. Based on the latest financial reports, Biofrontera Inc (BFRI) has total liabilities worth $18.11 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BFRI asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Biofrontera Inc (2019–2025)
Total liabilities of Biofrontera Inc from 2019 to 2025. This chart illustrates how Biofrontera Inc's total liabilities have evolved over time, based on quarterly financial data.
Biofrontera Inc Competitors by Total Liabilities
The table below lists competitors of Biofrontera Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cardiex Ltd
AU:CDX
|
Australia | AU$10.39 Million |
|
ABERA BIOSCIENCE AB
F:8WK
|
Germany | €7.57 Million |
|
Mr. Onion
TWO:2740
|
Taiwan | NT$43.17 Million |
|
MESB Bhd
KLSE:7234
|
Malaysia | RM66.07 Million |
|
Venteny Fortuna International
JK:VTNY
|
Indonesia | Rp958.76 Billion |
|
Arcoma AB
ST:ARCOMA
|
Sweden | Skr26.30 Million |
|
Elementis PLC
LSE:ELM
|
UK | GBX470.87 Million |
|
OXE Marine AB
ST:OXE
|
Sweden | Skr163.98 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Biofrontera Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BFRI total asset value.
Liquidity & Leverage Metrics
Biofrontera Inc Total Liabilities Ratios Explained
Biofrontera Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.75 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biofrontera Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biofrontera Inc (2019–2025)
The table below shows the annual total liabilities of Biofrontera Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $18.08 Million | +2.35% |
| 2024-12-31 | $17.67 Million | -23.64% |
| 2023-12-31 | $23.14 Million | -14.32% |
| 2022-12-31 | $27.01 Million | -35.52% |
| 2021-12-31 | $41.88 Million | +128.73% |
| 2020-12-31 | $18.31 Million | -68.93% |
| 2019-12-31 | $58.93 Million | -- |
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquarte… Read more